Butterfly Network (BFLY) investor relations material

Business overview and technology innovation

• Point-of-care ultrasound devices enable imaging at the patient’s location, democratizing access and reducing healthcare costs.

• Semiconductor-based ultrasound technology allows dynamic, programmable imaging for multiple clinical applications.

• Digital acquisition and cloud-based architecture revolutionize traditional ultrasound, similar to the shift from film to digital photography.

• Over 150,000 devices sold, with strong adoption across diverse medical settings and increasing brand recognition.

• Modern SaaS platform integrates with hospital systems, supporting compliance and revenue capture.

Strategic growth and AI integration

• AI and LLM models are being developed to simplify image acquisition and interpretation, addressing key ultrasound challenges.

• Recent FDA approval for an AI-powered blind sweep application highlights regulatory and technological leadership.

• Expansion into home care and service businesses is expected to materially contribute by 2027.

• Licensing the ultrasound chip to third parties through the Embedded program expands total addressable market from $30B to $35B.

• Partnerships with disclosed and undisclosed companies, plus ongoing discussions with 40+ others, drive future growth.

Financial performance and outlook

• Embedded segment now represents 20–25% of revenue, with expectations for further growth.

• Recent financial turnaround includes doubling revenue over three years, gross margins in the high 60s, and reduced cash burn.

• Last quarter saw 25% revenue growth, 600 basis point margin improvement, and reduced losses.

• Strong balance sheet and focus on cash management position the company for break-even and value generation.